Chronic asthma

This study tests a new medicine called SHR-1703 to see if it can reduce asthma attacks in people with eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. About 400 participants aged 12 and older who already use daily inhaled steroids and othe…

This Phase 2 trial tests whether adding rademikibart (a shot) to standard care can help adults and teens with asthma and type 2 inflammation avoid hospital visits or needing more steroids during an attack. About 160 participants will receive either the drug or a placebo. The main…

This study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…

This study tests whether a six-month course of dupilumab can calm the immune system enough for patients with severe olive pollen asthma to then benefit from standard allergy immunotherapy. Researchers will use advanced molecular profiling to understand how the treatment restores …

This study looks at whether people with severe asthma who start taking tezepelumab can safely lower their dose of inhaled corticosteroids. Researchers will track steroid use, asthma control, and flare-ups over 12 months in a real-world setting. The goal is to see if tezepelumab c…

This study tests whether benralizumab, an injected drug, can reduce asthma attacks in children aged 6 to 17 with severe eosinophilic asthma. About 200 participants will receive either benralizumab or a placebo, and researchers will track how long it takes for their first asthma f…

This study tests an experimental drug called povorcitinib in 240 adults with moderate to severe asthma that is not well controlled by current treatments. Participants will receive one of three doses of the drug or a placebo for 24 weeks. The main goal is to see if the drug improv…

This study tests whether the drug tezepelumab can help people with severe asthma reduce their daily maintenance inhaler dose without losing control of their asthma. About 326 adolescents and adults will receive tezepelumab injections and then try to step down their usual inhaler …

This study tests a new medicine called SHR-1905 for people with severe asthma that is not well controlled by current treatments. About 260 adults will receive either the drug or a placebo to see if it reduces asthma attacks and improves breathing and quality of life. The goal is …

This study is for adults with severe asthma who finished the earlier VALIANT trial. It tests the long-term safety and effectiveness of verekitug, a drug given as a shot. About 396 people are taking part. The main goal is to see if verekitug is safe over time and if it can reduce …

This study follows 125 people aged 12 and older with severe asthma who are starting tezepelumab in Russia. Over 52 weeks, researchers will track how well their symptoms are controlled using a standard questionnaire. The goal is to see how the drug works outside of clinical trials…

This study tests a smartphone app designed to make asthma easier to manage for 370 teenagers and young adults. The app is a digital version of an asthma action plan, helping users track symptoms and follow treatment guidelines. The goal is to see if using the app improves asthma …

This study tests a new antibody drug (called 610) for adults with severe asthma that is not well controlled by standard inhalers. About 225 participants will receive either the drug or a placebo to see if it improves lung function and reduces asthma attacks over 52 weeks. The dru…

This study aimed to see if a new lower-dose asthma inhaler (formoterol 6 mcg/fluticasone 125 mcg) works as well as an existing one (formoterol 6 mcg/budesonide 200 mcg) for people aged 12 and older with moderate asthma. The trial was withdrawn before any participants were enrolle…

This Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lun…

This observational study is collecting data from 315 patients in Italy who started treatment with tezepelumab for severe uncontrolled asthma. The goal is to describe their characteristics, medical history, and how their asthma exacerbation rates change over 12 to 24 months. It is…

This study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizu…

This study looks at how dupilumab, a drug for severe asthma, is actually used by patients in France. Researchers will analyze health records of about 35,000 people to describe their characteristics, healthcare costs, and steroid use before and after starting the drug. The goal is…

This study watches 100 people with severe asthma who are taking biologic drugs. Researchers measure how the body reacts to the drug and whether it affects asthma attacks. The goal is to learn more about drug effectiveness and safety.

This study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…

This study uses artificial intelligence and natural language processing to scan electronic health records and identify people with severe asthma. Researchers will compare the AI's findings to diagnoses made by doctors. The goal is to improve how severe asthma is detected and make…

This study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…

This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…

This study was designed to compare certain immune cells (called ILC2) in the lungs of children with severe asthma versus children without asthma. The goal was to see if these cells are higher in asthmatic children and if they relate to other markers of airway inflammation. Howeve…

This study follows 362 children with severe asthma to identify different types of the disease and what makes it worse. Researchers will track their health from childhood into adulthood to see how asthma changes over time. The goal is to find risk factors and improve treatment str…